FDA-cleared profile

Synapse 3D, Synapse 3D Base Tools v6.1

Fujifilm Corporation · Radiological images; modality varies or is not specified in FDA list · FDA-cleared (510(k))

Authorized purpose: Synapse 3D Base Tools is medical-imaging software that provides trained medical professionals tools to aid reading, interpreting, reporting, and treatment planning. It accepts DICOM images from imaging devices including CT, MR, CR, US, NM, PT, and XA, and provides viewing, volume rendering, multiplanar reconstruction, fusion, subtraction, segmentation, measurements, annotations, reporting, image management, and modality-specific CT and MR tools. It is not intended for primary diagnostic interpretation of mammography images.

Clinical role
Multimodality image viewing, processing, analysis, measurement, comparison, and reporting under professional review.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Patient anatomy represented in supported DICOM CT, MR, CR, US, NM, PT, and XA images; mammography excluded
Key limitation
Keep in mind: The exact labeling excludes use with or primary diagnostic interpretation of mammography images; supported modality-specific tools and downstream decisions require professional review.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Synapse 3D Base Tools is medical-imaging software that provides trained medical professionals tools to aid reading, interpreting, reporting, and treatment planning. It accepts DICOM images from imaging devices including CT, MR, CR, US, NM, PT, and XA, and provides viewing, volume rendering, multiplanar reconstruction, fusion, subtraction, segmentation, measurements, annotations, reporting, image management, and modality-specific CT and MR tools. It is not intended for primary diagnostic interpretation of mammography images.
  • Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Patient anatomy represented in supported DICOM CT, MR, CR, US, NM, PT, and XA images; mammography excluded Input: Supported DICOM CT, MR, PET, SPECT, X-ray, ultrasound, or other labeled medical-image inputs.
  • Who uses it?Intended users: Trained physicians, radiologists, technologists, and other medical-image professionals.
  • What does the software produce?Output: Multimodality images, fused views, quantitative results, contours, measurements, and reports for professional review.
  • What is its most important limitation?Key limitation: The exact labeling excludes use with or primary diagnostic interpretation of mammography images; supported modality-specific tools and downstream decisions require professional review.

Clinical takeaway. Clinical role: Synapse 3D Base Tools is medical-imaging software that provides trained medical professionals tools to aid reading, interpreting, reporting, and treatment planning. It accepts DICOM images from imaging devices including CT, MR, CR, US, NM, PT, and XA, and provides viewing, volume rendering, multiplanar reconstruction, fusion, subtraction, segmentation, measurements, annotations, reporting, image management, and modality-specific CT and MR tools. It is not intended for primary diagnostic interpretation of mammography images.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports non-clinical software verification and validation (system functionality, component, verification, integration, usability, installation/upgrade, labeling and risk-mitigation testing) plus benchmark performance testing on actual clinical images to show that the semi-automatic or automatic segmentation, detection and registration functions achieved the expected accuracy; all tests passed according to the design specifications. The document states the device does not require clinical studies. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Synapse 3D Base Tools is medical-imaging software that provides trained medical professionals tools to aid reading, interpreting, reporting, and treatment planning. It accepts DICOM images from imaging devices including CT, MR, CR, US, NM, PT, and XA, and provides viewing, volume rendering, multiplanar reconstruction, fusion, subtraction, segmentation, measurements, annotations, reporting, image management, and modality-specific CT and MR tools. It is not intended for primary diagnostic interpretation of mammography images.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Multimodality image viewing, processing, analysis, measurement, comparison, and reporting under professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported DICOM CT, MR, PET, SPECT, X-ray, ultrasound, or other labeled medical-image inputs.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Multimodality images, fused views, quantitative results, contours, measurements, and reports for professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Clinical image-review and post-processing environments within the labeled workflow.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Trained physicians, radiologists, technologists, and other medical-image professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The exact labeling excludes use with or primary diagnostic interpretation of mammography images; supported modality-specific tools and downstream decisions require professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports non-clinical software verification and validation (system functionality, component, verification, integration, usability, installation/upgrade, labeling and risk-mitigation testing) plus benchmark performance testing on actual clinical images to show that the semi-automatic or automatic segmentation, detection and registration functions achieved the expected accuracy; all tests passed according to the design specifications. The document states the device does not require clinical studies. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Testing for verification and validation involved system level functionality test, component testing, verification testing, integration testing, usability testing, installation/upgrade testing, labeling testing, as well as the testing for risk mitigations" … "benchmark performance testing was conducted using actual clinical images to help demonstrate that the semi-automatic or automatic segmentation, detection, and registration functions implemented in Synapse 3D Base Tools achieved the expected accuracy performance.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports non-clinical software verification and validation (system functionality, component, verification, integration, usability, installation/upgrade, labeling and risk-mitigation testing) plus benchmark performance testing on actual clinical images to show that the semi-automatic or automatic segmentation, detection and registration functions achieved the expected accuracy; all tests passed according to the design specifications. The document states the device does not require clinical studies. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Testing for verification and validation involved system level functionality test, component testing, verification testing, integration testing, usability testing, installation/upgrade testing, labeling testing, as well as the testing for risk mitigations" … "benchmark performance testing was conducted using actual clinical images to help demonstrate that the semi-automatic or automatic segmentation, detection, and registration functions implemented in Synapse 3D Base Tools achieved the expected accuracy performance.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K203103 FDA decision evidence package for Synapse 3D, Synapse 3D Base Tools v6.1

  • DesignFDA decision evidence and product verification described in the exact submission or PMA decision record.
  • PopulationPatient anatomy represented in supported DICOM CT, MR, CR, US, NM, PT, and XA images; mammography excluded
  • Scopeexact submission
  • Tested versionSynapse 3D, Synapse 3D Base Tools v6.1 configuration described in K203103
  • IndependenceSponsor or vendor study

K203103

FDA decision material is manufacturer-submitted regulatory evidence. It is not independent clinical validation unless the exact source expressly establishes that distinction; local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K203103 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported DICOM CT, MR, PET, SPECT, X-ray, ultrasound, or other labeled medical-image inputs.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K203103: Synapse 3D, Synapse 3D Base Tools v6.1

  2. Routing

    Source context, not route validation: The exact FDA package describes Synapse 3D Base Tools as connected through the DICOM standard to medical devices and a PACS, retrieving image data via DICOM-based network communication; new images can be printed on DICOM or Windows printers, and it can be integrated with Fujifilm's Synapse PACS. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "Synapse 3D Base Tools is connected through DICOM standard to medical devices and to a PACS system storing data generated by these medical devices, and it retrieves image data via network communication based on the DICOM standard." … "Images newly created by Synapse 3D Base Tools (V6.1) not only can be displayed on a display, but also can be printed on a hardcopy using a DICOM printer or a Windows printer.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA 510(k) decision material K203103: Synapse 3D, Synapse 3D Base Tools v6.1

  3. AI processing

    Source context, not route validation: The exact FDA package describes Synapse 3D Base Tools (V6.1) as application software running on a Windows server/client configuration installed on commercial general-purpose Windows-compatible computers, with retrieved images stored on a local disk it manages. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "The 3D image analysis software Synapse 3D Base Tools (V6.1) is medical application software running on Windows server/client configuration installed on commercial general-purpose Windows-compatible computers." … "The retrieved image data are stored on the local disk managed by Synapse 3D Base Tools (V6.1)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA 510(k) decision material K203103: Synapse 3D, Synapse 3D Base Tools v6.1

  4. Returned objects

    Source context, not route validation: Multimodality images, fused views, quantitative results, contours, measurements, and reports for professional review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K203103: Synapse 3D, Synapse 3D Base Tools v6.1

  5. Viewer/worklist/report

    Unresolved route: Multimodality images, fused views, quantitative results, contours, measurements, and reports for professional review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K203103: Synapse 3D, Synapse 3D Base Tools v6.1

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes Synapse 3D Base Tools (V6.1) as application software running on a Windows server/client configuration installed on commercial general-purpose Windows-compatible computers, with retrieved images stored on a local disk it manages. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The 3D image analysis software Synapse 3D Base Tools (V6.1) is medical application software running on Windows server/client configuration installed on commercial general-purpose Windows-compatible computers." … "The retrieved image data are stored on the local disk managed by Synapse 3D Base Tools (V6.1)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact FDA package describes Synapse 3D Base Tools as connected through the DICOM standard to medical devices and a PACS, retrieving image data via DICOM-based network communication; new images can be printed on DICOM or Windows printers, and it can be integrated with Fujifilm's Synapse PACS. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Synapse 3D Base Tools is connected through DICOM standard to medical devices and to a PACS system storing data generated by these medical devices, and it retrieves image data via network communication based on the DICOM standard." … "Images newly created by Synapse 3D Base Tools (V6.1) not only can be displayed on a display, but also can be printed on a hardcopy using a DICOM printer or a Windows printer.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Security
Fujifilm Healthcare Americas' Enterprise Imaging security center states that Fujifilm received a SOC 2 Type II report for the previous 12-month period and provides Manufacturer Disclosure Statement for Medical Device Security (MDS2) documentation for Synapse products through its customer portal and a security documentation request form, covering ePHI maintenance/storage/transmission, data backup and removable media, security patch and antivirus installation, remote service access, and ePHI audit logs.
  • Product family
  • Checked 2026-10-27

Vendor statement, not an attestation; the SOC 2 report and MDS2 documents were not read (portal/request-gated). Page scope is Fujifilm's Enterprise Imaging (Synapse) line; this entry is a Synapse-named product. Exact-release scope is not established. Not applied to ECHELON (MRI) or Sonosite (ultrasound) entries.

Training
Only trained physicians, radiologists, technologists, and other medical-image professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K203103 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The exact labeling excludes use with or primary diagnostic interpretation of mammography images; supported modality-specific tools and downstream decisions require professional review.
  • Exact FDA submission
  • Checked 2026-09-04

This is buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K203103 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared or authorized release includes them.

Deployment boundary

The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.

exact submission · checked 2026-09-04

FDA-described topology does not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The exact public integration contract remains incomplete; establish and test supported input, output, identity, routing, archive, and downtime behavior locally.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The exact labeling excludes use with or primary diagnostic interpretation of mammography images; supported modality-specific tools and downstream decisions require professional review.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

exact submission · checked 2026-09-04

No exact-product price or reimbursement determination was promoted.

Lifecycle monitoring

Monitor K203103 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The exact labeling excludes use with or primary diagnostic interpretation of mammography images; supported modality-specific tools and downstream decisions require professional review.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K203103
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiological images; modality varies or is not specified in FDA list
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Patient anatomy represented in supported DICOM CT, MR, CR, US, NM, PT, and XA images; mammography excluded
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2021-02-09
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No exact-product reimbursement determination was promoted in this timeboxed review. Verify payer, site-of-service, coding, coverage, and local payment assumptions independently.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

6 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K203103: Synapse 3D, Synapse 3D Base Tools v6.1

    U.S. Food and Drug Administration - Published 2021-02-09 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. Fujifilm Healthcare Americas: Enterprise Imaging Security Documentation

    Fujifilm Healthcare Americas - Accessed 2026-10-27

    Scope: security

Research history

  1. K203103 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K243651

VersaViewer

GE Medical Systems SCS

Authorized purpose: VersaViewer supports two-dimensional, three-dimensional, and four-dimensional medical-image series processing and analysis through customizable layouts, multimodality review, and measurements for trained healthcare professionals; it is not for displaying digital mammography for diagnosis.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Multi-region anatomy represented in CT, MR, PET, NM, XA, and other supported studies
Decision
2025-04-21
FDA-cleared K222174

RadioLens v1.0

Synapsica

Authorized purpose: RadioLens v1.0 is a medical diagnostic application for displaying, processing, storing, and transferring DICOM data other than mammography, with filtering, digital manipulation, and quantitative measurements; its optional SpindleX module analyzes potential vertebral displacement in adult cervical or lumbar spine stress X-rays and calculates measurements related to spinal-ligament injury leading to subluxation.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Spine, including cervical and lumbar vertebrae; general DICOM images excluding mammography
Decision
2023-03-28
FDA-cleared K222428

Syngo Dynamics (Version VA40F)

Siemens Medical Solutions USA, Inc.

Authorized purpose: Syngo Dynamics VA40F is a multimodality, vendor-agnostic cardiology image and information system for medical-image management and processing, with post-processing functions for image manipulation and quantification supporting interpretation and analysis for disease detection, diagnosis, and patient management within a healthcare institution's network.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Anatomy represented in multimodality cardiology medical images, excluding U.S. digital mammography diagnosis
Decision
2022-11-14
FDA-cleared K173588

Illumeo System

Philips Medical Systems Technologies, Ltd.

Authorized purpose: Illumeo is an image-management system for trained professionals, including radiologists. It is a software package used with general-purpose computing hardware to acquire, store, distribute, process, and display images and associated data throughout a clinical environment, including digital image processing, measurement, manipulation, quantification, communication, and storage. It is not to be used for mammography.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Images and associated data represented in the clinical environment; mammography excluded
Decision
2018-01-12

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history